Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2025)

Crinetics Pharmaceuticals has reported Net Cash Flow over the past 9 years, most recently at -$9.8 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$9.8 million for Q4 2025, up 81.49% from a year ago — trailing twelve months through Dec 2025 was -$163.4 million (down 177.94% YoY), and the annual figure for FY2025 was -$163.4 million, down 177.94%.
  • Net Cash Flow for Q4 2025 was -$9.8 million at Crinetics Pharmaceuticals, down from $57.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CRNX hit a ceiling of $341.0 million in Q1 2024 and a floor of -$170.0 million in Q1 2025.
  • Median Net Cash Flow over the past 5 years was -$5.7 million (2023), compared with a mean of $442750.0.
  • Peak annual rise in Net Cash Flow hit 3902.19% in 2024, while the deepest fall reached 5613.71% in 2024.
  • Crinetics Pharmaceuticals' Net Cash Flow stood at $39.2 million in 2021, then crashed by 95.5% to $1.8 million in 2022, then crashed by 5091.37% to -$87.9 million in 2023, then surged by 40.02% to -$52.7 million in 2024, then soared by 81.49% to -$9.8 million in 2025.
  • The last three reported values for Net Cash Flow were -$9.8 million (Q4 2025), $57.2 million (Q3 2025), and -$40.8 million (Q2 2025) per Business Quant data.